Stifel cuts Scotts Miracle-Gro stock rating on inventory concerns

Stifel downgraded Scotts Miracle-Gro (SMG) to a Hold rating with a $71 price target, citing concerns about U.S. consumer revenue guidance and potential channel inventory risks despite the company's reaffirmed full-year EBITDA guidance of $570 to $590 million. This decision contrasts with Truist Securities' maintained Buy rating and increased price target to $75, driven by strong consumer point-of-sale sales growth and favorable weather comparisons. While SMG's Q2 2025 EPS slightly beat expectations, revenue missed estimates, leading to mixed sentiment among analysts regarding the company's fiscal year 2025 upside and uncertain fiscal year 2026.

Analysis

Stifel analysts have shifted their stance on Scotts Miracle-Gro (NYSE: SMG), downgrading the stock from Buy to Hold and adjusting the price target to $71 from $70. This revision follows a recent 13.4% surge in SMG's shares, significantly outperforming the S&P 500's 0.5% gain. The primary driver for Stifel's caution is the updated U.S. consumer revenue guidance, which they interpret as signaling potential risks associated with channel inventory, potentially capping fiscal year 2025 upside and clouding the outlook for an already uncertain fiscal year 2026. Despite SMG's solid $3.45 billion annual revenue and a "GOOD" overall financial health score from InvestingPro, Stifel believes the risk/reward profile now supports a neutral position, especially as shares trade at 17 times projected fiscal year 2026 earnings per share, aligning with Consumer Staples peers. This cautious view considers peak earnings growth during the company's recovery phase and the influence of investment plans and below-the-line items on their below-consensus outlook. Scotts Miracle-Gro's second-quarter 2025 results showed a slight earnings per share beat at $3.98 (versus $3.94 forecasted) but a revenue miss, with $1.42 billion reported against an expected $1.5 billion. The company, however, reaffirmed its full-year EBITDA guidance of $570 to $590 million and fiscal year 2025 guidance, emphasizing consumer point-of-sale unit growth and an anticipated $30 million decrease in interest expense. Other analyst actions present a mixed picture: Truist Securities maintained a Buy rating and raised its price target to $75, citing strong consumer point-of-sale growth and favorable weather, while UBS kept a Neutral rating with a $54 price target, noting strong peer performance and expected margin recovery in fiscal year 2026. The company plans to provide further strategic updates, including e-commerce advancements, at an upcoming conference.

Key Decisions for Investors

• Investors should consider the current valuation, with SMG trading at parity with consumer staples peers, and Stifel's concerns regarding channel inventory potentially limiting near-term upside.
• Monitor upcoming company updates, particularly from the planned conference on long-term strategy and e-commerce, as these could provide clarity on future growth drivers and address current analyst concerns.
• Given the mixed analyst ratings and the balance between reaffirmed EBITDA guidance versus revenue softness and inventory risks, a cautious approach may be warranted, closely tracking U.S. consumer revenue trends and inventory management.
• Assess the divergent analyst price targets ($54 from UBS, $71 from Stifel, $75 from Truist) and their underlying rationales to form a comprehensive view on potential risk and reward.